Currently available medications could be enough to end the HIV epidemic in the United States, provided people can access and ...

A new analysis finds that generic lenacapavir, a twice-yearly HIV preventive treatment, could be mass produced for just $25 ...

Tucked away in a modest office in the heart of Johannesburg’s Central Business District lies the nerve centre of the world’s ...

This article, Part One of the Mercury’s Pulse Check series, was produced as a project for the USC Annenberg Center for Health ...

Dr Joel Steingo of TB HIV Care says Lenacapavir could be a breakthrough in reducing infections, especially at a time when ...

It will bring support services to Bangor, while another program is expanding HIV and AIDS services to all but two counties in ...

It will bring support services to Bangor, while another program is expanding HIV and AIDS services to all but two counties in ...

Kameron Gilchrist sprayed his own HIV-tainted blood into the eyes of two hospital workers in North Carolina and was collared ...

Now, the fight against HIV/AIDS is not just about governments and global health organisations anymore; it is a deeply personal one. And it is all about the choices you make, the conversations you have ...

The drug can be produced for as little as $25 per person annually, but even at $2000 per person, it can reduce new US infections almost entirely, a researcher says.

Gilead Sciences (NASDAQ:GILD) has discontinued a Phase 1 trial for GS-1219, a long-acting subcutaneously delivered treatment ...

From discontinued insulin pens to overpriced TB drugs, meet the young South African holding drug makers to account on behalf ...